Abstract
Botulinum toxin has long been known for its paralytic effects on the human voluntary musculature via inhibition of acetylcholine release at neuromuscular junctions. Its original clinical use for the treatment of strabismus has expanded significantly to include neurological conditions related to muscle hyperactivity and/or spasticity (e.g., dystonia, spasticity, tics, tremor, dysphonia). Recently, botulinum toxin has been shown to impact autonomic disorders by acting at acceptors on glands and smooth muscle, and consequently it has been used in the management of a number of other conditions including hypersecretory disorders, pain syndromes, detrusor sphinchter dyssenergia or overactivity and gastointestinal smooth muscle/sphincter spasm; it may also reduce pain in patients for whom it is used to treat these and other primary conditions. This article will review the pharmacology and formulations of botulinum toxins as well as data from clinical trials demonstrating their efficacy for numerous conditions based on their effects on cholinergic synapses outside the motor nervous system.
Current Pharmaceutical Design
Title: Current Clinical Applications of Botulinum Toxin
Volume: 15 Issue: 31
Author(s): Daniel D. Truong, Andrea Stenner and Gerhard Reichel
Affiliation:
Abstract: Botulinum toxin has long been known for its paralytic effects on the human voluntary musculature via inhibition of acetylcholine release at neuromuscular junctions. Its original clinical use for the treatment of strabismus has expanded significantly to include neurological conditions related to muscle hyperactivity and/or spasticity (e.g., dystonia, spasticity, tics, tremor, dysphonia). Recently, botulinum toxin has been shown to impact autonomic disorders by acting at acceptors on glands and smooth muscle, and consequently it has been used in the management of a number of other conditions including hypersecretory disorders, pain syndromes, detrusor sphinchter dyssenergia or overactivity and gastointestinal smooth muscle/sphincter spasm; it may also reduce pain in patients for whom it is used to treat these and other primary conditions. This article will review the pharmacology and formulations of botulinum toxins as well as data from clinical trials demonstrating their efficacy for numerous conditions based on their effects on cholinergic synapses outside the motor nervous system.
Export Options
About this article
Cite this article as:
Truong D. Daniel, Stenner Andrea and Reichel Gerhard, Current Clinical Applications of Botulinum Toxin, Current Pharmaceutical Design 2009; 15 (31) . https://dx.doi.org/10.2174/138161209789271843
DOI https://dx.doi.org/10.2174/138161209789271843 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Editorial [ Medicines Da Vinci Code: Deciphering the Intricate Origins of Clinical Neurovascular Pathology K. Maiese ]
Current Neurovascular Research Inhibiting the Secretion of Hepatitis B Surface Antigen (HBsAg) to Treat Hepatitis B Infection- a Review
Infectious Disorders - Drug Targets Potential Therapeutic Benefits of Maintaining Mitochondrial Health in Peripheral Neuropathies
Current Neuropharmacology Regulation of Apoptosis and Activity of the Osteoclast
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Neuroferritinopathy: Update on Clinical Features and Pathogenesis
Current Drug Targets Overview of Tyrosine Hydroxylase in Parkinson’s Disease
CNS & Neurological Disorders - Drug Targets Cannabinoids and Neurodegenerative Diseases
CNS & Neurological Disorders - Drug Targets The Endocannabinoid System in Parkinsons Disease
Current Pharmaceutical Design Targeting the SH2 Domain-Containing Inositol Phosphatase (SHIP) for Therapy
Current Enzyme Inhibition Oleic Acid in Olive Oil: From a Metabolic Framework Toward a Clinical Perspective
Current Pharmaceutical Design The HIV Entry Inhibitors Revisited
Current Medicinal Chemistry Neuroprotective Effect of Atremorine in an Experimental Model of Parkinson’s Disease
Current Pharmaceutical Design Unraveling the Structure and Function of G Protein-Coupled Receptors Through NMR Spectroscopy
Current Pharmaceutical Design Postpartum Depression in Women with the FMR1 Premutation
Current Psychiatry Reviews Aminoglycoside-Induced Ototoxicity
Current Pharmaceutical Design Elevated Homocysteine Levels in Parkinsons Disease: Is there Anything Besides L-Dopa Treatment?
Current Medicinal Chemistry Harnessing the Potential of Mesenchymal Stem Cells for IVD Regeneration
Current Stem Cell Research & Therapy Clinical Importance of Assessment of Type 2 Diabetes Mellitus with Visceral Obesity. A Japanese Perspective
Current Diabetes Reviews Artificial Organs: A New Option for Treating Osteoarthritis
Current Drug Delivery Disentangling the Intricacies of Migraine: A Review
CNS & Neurological Disorders - Drug Targets